Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Lagoon randomized 724 second-line relapsed SCLC patients 1:1:1 to lurbinectedin, lurbinectedin+irinotecan, or topotecan/irinotecan control, and failed the primary OS endpoint in both investigational ...

Novavax discusses how new vaccine technologies are reducing side effects, lowering costs, and enhancing immune response. Advertisement ...

A look at the performance of the top 15 companies across seven business-key metrics, including the latest standouts in market capitalization and creating shareholder value. Welcome to Pharmaceutical ...

While Eli Lilly continues to ride an historic stretch of company growth and performance in the annals of Big Pharma, the now ...

We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...

Most terminated trials stop for enrollment and funding failures, not negative efficacy or safety, making data-collection cost ...

The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...